Project description DEENESFRITPL Monoclonal antibodies against COVID-19 Previous experience on SARS and MERS coronaviruses is proving instrumental for the rapid development of new diagnostic, prophylactic and therapeutic intervention strategies against COVID-19. The EU-funded MANCO project is building on technology generated during the ongoing IMI-funded ZAPI project on monoclonal antibodies against coronaviruses. The researchers of MANCO will identify specific monoclonal antibodies against the new coronavirus and validate them at the preclinical level. The idea is to advance one lead prophylactic and/or therapeutic monoclonal antibody into a Phase I clinical trial and make results available within two years of the start of the project. Show the project objective Hide the project objective Objective "Lessons learned from, and intervention efforts against SARS coronavirus (CoV), MERS-CoV and other emerging viruses provide invaluable information to accelerate the coordinated response against 2019 novel (2019 -n)CoV and the rapid development and manufacture of new diagnostic, prophylactic and therapeutic intervention strategies. A -promising approach to both patient management of emerging viral infections and to better preparedness and response to emerging epidemics is the use of monoclonal antibodies. MANCO aims at contributing to the rapid international response against 2019-nCoV, through preclinical and clinical evaluation of monoclonal antibodies against 2019-nCoV. MANCO will build on and leverage outstanding results from ongoing IMI-funded project #115760 ZAPI, including recently-discovered broadly cross-reactive H2L2 monoclonal antibodies against betacoronaviruses and an established pipeline for rapid identification of specific H2L2 monoclonal antibodies against 2019-nCoV; antibodies that will be selected to proceed to GMP manufacturing in high-yield CHO cell-lines. This project furthermore builds on ZAPI consortium’s experience and expertise for the development and establishment of relevant animal models, to ensure preclinical efficacy and safety, including absence of antibody-dependent enhancement, an issue seen to occur in some immunization studies against feline and SARS CoVs. Based on the generated preclinical data, MANCO will advance one lead (prophylactic and/or therapeutic) monoclonal antibody into a Phase I clinical trial that can be completed within two years of the start of the project, by leveraging clinical expertise, infrastructure and network currently in place for ongoing CEPI-funded projects on candidate vaccines against MERS-CoV (#INID1801) and Rift Valley Fever virus (#INLA1901), and H2020-funded projects on improved vaccines targeting the elderly (ISOLDA #848166) and on universal influenza vaccines, including in LMICs (ENDFLU #874650)." Fields of science medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronavirusesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SC1-PHE-CORONAVIRUS-2020 - Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic Call for proposal H2020-SC1-PHE-CORONAVIRUS-2020 See other projects for this call Funding Scheme RIA - Research and Innovation action Coordinator ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Net EU contribution € 200 000,00 Address Dr molewaterplein 40 3015 GD Rotterdam Netherlands See on map Region West-Nederland Zuid-Holland Groot-Rijnmond Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (7) Sort alphabetically Sort by Net EU contribution Expand all Collapse all HARBOUR ANTIBODIES BV Netherlands Net EU contribution € 279 866,25 Address Stationsplein 45, a4.004 3013 AK Rotterdam See on map Region West-Nederland Zuid-Holland Groot-Rijnmond Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 UNIVERSITEIT UTRECHT Netherlands Net EU contribution € 272 126,96 Address Heidelberglaan 8 3584 CS Utrecht See on map Region West-Nederland Utrecht Utrecht Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER Germany Net EU contribution € 129 999,63 Address Bunteweg 2 30559 Hannover See on map Region Niedersachsen Hannover Region Hannover Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS Spain Net EU contribution € 233 511,25 Address Calle serrano 117 28006 Madrid See on map Region Comunidad de Madrid Comunidad de Madrid Madrid Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE(IABS-EU) France Net EU contribution € 131 625,00 Address 24 rue jean baldassini 69393 Lyon See on map Region Auvergne-Rhône-Alpes Rhône-Alpes Rhône Activity type Other Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CR2O BV Netherlands Net EU contribution € 1 614 826,50 Address Bisonspoor 3002, c701 3605 LT Maarssen See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region West-Nederland Utrecht Utrecht Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 FINOVATIS France Net EU contribution € 172 625,66 Address 62 rue de bonnel 69003 Lyon See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Auvergne-Rhône-Alpes Rhône-Alpes Rhône Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
